Stockscreener 앱 받기
5.60
0.00%
0.00
시간 외 거래:
5.93
0.33
+5.89%
4 D Molecular Therapeutics Inc 주식(FDMT)의 최신 뉴스
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population - Marketscreener.com
Breakthrough Eye Treatment Data: 4D Molecular's AMD Trial Results Coming February - StockTitan
Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) PT at $38.56 - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc.FDMT - Longview News-Journal
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Top US Penny Stocks To Watch In January 2025 - Simply Wall St
Cantor Fitzgerald Estimates FDMT FY2025 Earnings - MarketBeat
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Assenagon Asset Management S.A. Sells 889,884 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
FDMT stock touches 52-week low at $4.48 amid market challenges - MSN
4D Molecular Therapeutics' (FDMT) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Weiss Ratings Reaffirms “Sell (D-)” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
Weiss Ratings Reiterates Sell (D-) Rating for 8X8 (NASDAQ:EGHT) - Defense World
Weiss Ratings Reiterates “Sell (D-)” Rating for 89bio (NASDAQ:ETNB) - Defense World
JPMorgan Chase & Co. Trims Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
FY2024 Earnings Estimate for FDMT Issued By Leerink Partnrs - Defense World
Equities Analysts Set Expectations for FDMT FY2029 Earnings - Defense World
FY2029 Earnings Estimate for FDMT Issued By HC Wainwright - MarketBeat
Leerink Partnrs Has Bullish Outlook for FDMT FY2024 Earnings - MarketBeat
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Raised by Barclays PLC - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Lowered to “Market Perform” Rating by BMO Capital Markets - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given Buy Rating at HC Wainwright - Defense World
4D Molecular Therapeutics' SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Morgan Stanley Lowers 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $6.00 - MarketBeat
4D Molecular Therapeutics stock hits 52-week low at $5.2 - Investing.com India
4D Molecular downgraded at BMO on limited population for wet AMD candidate - MSN
4D Molecular Therapeutics (NASDAQ:FDMT) Stock Rating Lowered by BMO Capital Markets - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - MarketBeat
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 6 Analysts - Benzinga
Leerink cuts 4D Molecular Therapeutics price target following pipeline updates - Investing.com Australia
Leerink cuts 4D Molecular Therapeutics price target following pipeline updates By Investing.com - Investing.com South Africa
BMO Capital downgrades 4D Molecular Therapeutics stock to Market Perform, cites challenges - Investing.com Canada
BMO Capital downgrades 4D Molecular Therapeutics stock to Market Perform, cites challenges By Investing.com - Investing.com South Africa
4D Molecular Therapeutics refocuses on key drug candidates By Investing.com - Investing.com Australia
4D Molecular, FDA agree on phase 3 design for DME candidate - Seeking Alpha
FDMT4D Molecular Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
4D Molecular Therapeutics refocuses on key drug candidates - Investing.com India
4D Molecular Therapeutics Streamlines Pipeline, Advances Key Eye Disease & CF Programs with $506M Cash - StockTitan
Scrip Asks… What Does 2025 Hold For Biopharma? Part 1: The State Of The Biopharma Industry - News & Insights
Brokerages Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Target Price at $42.56 - Defense World
Brokerages Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Price Target at $42.56 - MarketBeat
Geode Capital Management LLC Sells 24,346 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Barclays PLC Has $1.24 Million Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics stock hits 52-week low at $5.57 By Investing.com - Investing.com Canada
Fmr LLC Sells 1,012,123 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Analyzing Scholar Rock (NASDAQ:SRRK) and 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
Critical Review: 4D Molecular Therapeutics (NASDAQ:FDMT) & Candel Therapeutics (NASDAQ:CADL) - Defense World
State Street Corp Boosts Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) dropped from S&P Biotechnology Select Industry Index - Marketscreener.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
What 5 Analyst Ratings Have To Say About 4D Molecular Therapeutics - Benzinga
Bank of America Has Lowered Expectations for 4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price - MarketBeat
Short Interest in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Increases By 8.8% - MarketBeat
3.95%
2.39%
자본화:
|
볼륨(24시간):